DIFFUSE LARGE B CELL LYMPHOMA REFRACTORY
Clinical trials for DIFFUSE LARGE B CELL LYMPHOMA REFRACTORY explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE LARGE B CELL LYMPHOMA REFRACTORY trials appear
Sign up with your email to follow new studies for DIFFUSE LARGE B CELL LYMPHOMA REFRACTORY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to boost CAR-T safety in lymphoma patients
Disease control Recruiting nowThis early-stage trial tests whether giving radiation therapy and the antibiotic vancomycin before CAR-T cell therapy is safe and doable for people with large B-cell lymphoma. About 14 adults whose lymphoma has not responded or has come back will receive this combination. The goa…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA REFRACTORY
Phase: PHASE1 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Jul 02, 2026 03:00 UTC
-
New pill takes on rare, stubborn lymphoma
Disease control Recruiting nowThis early-phase trial is testing an oral drug called VK-2019 in 30 adults with a type of lymphoma (DLBCL) that is linked to the Epstein-Barr virus and has not responded to at least two prior treatments. Participants take the drug daily in 28-day cycles at one of three dose level…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA REFRACTORY
Phase: PHASE1 • Sponsor: Pierluigi Porcu • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New 'Double Punch' CAR T-Cell therapy takes on tough blood cancers
Disease control Recruiting nowThis early-phase trial is testing a new cell therapy called GF-CART01 for people with certain B-cell blood cancers (like lymphoma) that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target two cancer markers (CD…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA REFRACTORY
Phase: PHASE1 • Sponsor: GenomeFrontier Therapeutics TW Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New dual-targeting CAR t therapy takes on hard-to-treat lymphoma in phase 3 trial
Disease control Recruiting nowThis phase 3 trial tests a new CAR T-cell therapy called rondecabtagene autoleucel (ronde-cel) that targets two proteins (CD19 and CD20) on lymphoma cells. It is compared to standard CD19-targeting CAR T-cell therapy in 400 patients with relapsed or refractory large B-cell lympho…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA REFRACTORY
Phase: PHASE3 • Sponsor: Lyell Immunopharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New combo therapy aims to stop aggressive lymphoma relapse
Disease control Recruiting nowThis study tests whether adding a drug called golcadomide after standard CAR T-cell therapy can prevent aggressive large B-cell lymphoma from returning in patients at high risk of relapse. About 65 adults will receive golcadomide for 24 weeks starting 5 days after their CAR T-cel…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA REFRACTORY
Phase: PHASE2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug cocktail aims to boost CAR T-Cell success in lymphoma
Disease control Recruiting nowThis early-phase trial is testing whether adding two drugs—CC-99282 and rituximab—can help people with non-Hodgkin lymphoma who didn't get a good result from CAR T-cell therapy. The study will enroll 18 adults with relapsed or refractory B-cell lymphoma. Researchers are looking f…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA REFRACTORY
Phase: PHASE1 • Sponsor: Nathan Denlinger • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC